←Back to Expert Scholars
Translational Medicine / 转化医学Hereditary Cancer, Targeted Therapy
Mark Robson
MD
🏢Memorial Sloan Kettering Cancer Center🌐USA
Chief, Breast Medicine Service
100
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Mark Robson led the OlympiAD trial establishing olaparib for metastatic germline BRCA-mutated breast cancer, the first PARP inhibitor approval in this indication. He chairs the MSKCC breast medicine service and co-leads hereditary cancer research. His work informs international guidelines.
Share:
🧪Research Fields 研究领域
BRCA1
BRCA2
PARP inhibitors
OlympiAD
hereditary breast cancer
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Mark Robson 的研究动态
Follow Mark Robson's research updates
留下邮箱，当我们发布与 Mark Robson（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment